

Sequential allogenic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive Myeloid Sarcoma and Acute B-Lymphoblastic Leukemia

Giuliana Rizzuto¹, Matteo Leoncin², Silvia Imbergamo², Daniela Taurino³, Maria Caterina Micò⁴, Manuela Tosi⁴, Anna Michelato⁴, Ksenija Buklijas⁴, Orietta Spinelli⁴, Federico Lussana¹, Federica Lessi⁵, Marco Pizzi⁶, Laura Bonaldi⁷, Gianni Binotto⁵, Alessandro Rambaldi⁸, and Carmela Gurrieri⁵

¹ASST Papa Giovanni XXIII

²Università degli Studi di Padova

³Aziende Socio Sanitarie Territoriale Papa Giovanni XXIII

⁴Azienda Ospedaliera Papa Giovanni XXIII

⁵Università degli Studi di Padova

⁶Università degli Studi di Padova Scuola di Medicina e Chirurgia

⁷Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico

⁸University of Milan

August 8, 2021

Abstract

The translocation t(8;9)(p22;p24) results in the production of a chimeric PCM1-JAK2 fusion protein leading to the constitutive activation of the Janus Kinase 2 that renders this disease potentially sensitive to ruxolitinib. Here we report an interesting case of PCM1-JAK2 myeloproliferative neoplasm evolving in myeloid sarcoma and B precursor ALL.

Hosted file

Rizzutoetal_CaseReport_CCR.pdf available at <https://authorea.com/users/429689/articles/533328-sequential-allogenic-transplantation-and-ruxolitinib-maintenance-for-a-synchronous-pcm1-jak2-positive-myeloid-sarcoma-and-acute-b-lymphoblastic-leukemia>

